Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_assertion type Assertion NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_head.
- NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_assertion description "[In each category except for RARS, approximately half of the patients progressed, with a slightly less median time to progression in RAEB-T than for the other subtypes of MDS.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_provenance.
- NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_assertion evidence source_evidence_literature NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_provenance.
- NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_assertion SIO_000772 11960342 NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_provenance.
- NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_assertion wasDerivedFrom befree-20150227 NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_provenance.
- NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_assertion wasGeneratedBy ECO_0000203 NP781519.RAi2sxbA6RX2T-7KDa_o-XQ7RkLtH_mnuwVfbNBTgVvp8130_provenance.